Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290141 · ClinicalTrials.gov registry record · Phase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT06290141 is a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy that is actively recruiting participants, run by Sanofi. The registered enrollment target is 160 participants, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (10% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT06290141, a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG riliprubart
- DRUG IVIg
Study Locations (20)
New York
- Dent Neurologic Institute - Amherst- Site Number : 8400039 - Amherst
- Hospital for Special Surgery- Site Number : 8400041 - New York
- Columbia University Irving Medical Center- Site Number : 8400003 - New York
California
- Keck School of Medicine of University of Southern California- Site Number : 8400002 - Los Angeles
- University of California Irvine Medical Center- Site Number : 8400007 - Orange
Florida
- AdventHealth Orlando- Site Number : 8400006 - Orlando
- AdventHealth Site Number : 8400006 - Orlando
Michigan
- Henry Ford Hospital- Site Number : 8400025 - Detroit
- Michigan State University- Site Number : 8400038 - East Lansing
Ohio
- University of Cincinnati Medical Center- Site Number : 8400020 - Cincinnati
- University Hospitals Cleveland Medical Center- Site Number : 8400033 - Cleveland
Alabama
- Alabama Neurology Associates- Site Number : 8400019 - Homewood
Arizona
- Honor Health Scottsdale Osborn Medical Center- Site Number : 8400014 - Scottsdale
Connecticut
- Yale University School of Medicine- Site Number : 8400018 - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-08-21 |
| Est. Completion | 2029-01-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06290141
The ClinicalTrials.gov registry entry for NCT06290141 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (10% higher). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06290141 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06290141 about?
NCT06290141 is a clinical study titled "A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
What is the current status of trial NCT06290141?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2024-08-21. Estimated completion is 2029-01-12.
What conditions does trial NCT06290141 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT06290141?
The interventions under investigation include: Placebo (DRUG), riliprubart (DRUG), IVIg (DRUG).
Who is sponsoring clinical trial NCT06290141?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06290141 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
RECRUITING · Phase 3
-
IVIG vs SCIG in CIDP
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.